DISCOUNT-ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000KJ31RJ5

Delayed Deutsche Boerse AG 13:27:16 2024-06-05 EDT
231.2 EUR +0.23% Intraday chart for DISCOUNT-ZERTIFIKAT - ROCHE GS
Current month+2.29%
1 month+6.14%
Date Price Change
24-06-05 231.2 +0.23%
24-06-04 230.7 +1.33%
24-06-03 227.7 +0.72%
24-05-31 226 +0.66%
24-05-30 224.6 +0.63%

Delayed Quote Deutsche Boerse AG

Last update June 05, 2024 at 01:27 pm

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Citi Citi
WKN KJ31RJ
ISINDE000KJ31RJ5
Date issued 2023-12-27
Maturity 2024-12-19 (197 Days)
Parity 1 : 1
Emission price 232.8
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 241.8
Lowest since issue 214.6

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
236.1 CHF
Average target price
277.5 CHF
Spread / Average Target
+17.55%
Consensus